Journal of Integrated Research (Agriculture & Life Sciences) - Volume 01: 2026, Issue 1

Emerging Vesicular Nanocarriers for Tofacitinib: A Novel Approach to Enhancing Therapeutic Outcomes in Rheumatoid Arthritis

  • Published: 2026
Download PDF
Google Scholar

Authors

Shivani Pannu, Pooja, Reena, Rahul Sharm, Inderjeet Verma

DOI Number

–

Keywords

Tofacitinib, Vesicular drug delivery systems, Rheumatoid arthritis, Liposomes, Niosomes, Janus kinase inhibitors, Targeted drug delivery, Nanocarriers, Solid lipid nanoparticles, Nanomedicine

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent synovial inflammation and progressive joint destruction. While Tofacitinib, a Janus kinase (JAK) inhibitor, has emerged as an effective oral disease-modifying antirheumatic drug (DMARD), its systemic administration is often associated with suboptimal bioavailability, dose-related toxicity, and off-target effects. These challenges necessitate the development of advanced delivery strategies to enhance therapeutic efficacy while minimizing adverse effects.

Vesicular drug delivery systems such as liposomes, niosomes, ethosomes, transfersomes, and solid lipid nanoparticles (SLNs) offer promising platforms for targeted and controlled release of Tofacitinib. These nanocarriers can be engineered to improve drug encapsulation, increase stability, and facilitate site-specific delivery to inflamed joints via passive and active targeting mechanisms. Furthermore, their ability to cross biological barriers and achieve prolonged circulation enhances drug bioavailability and therapeutic index.

This review provides a comprehensive overview of the pharmacological profile of Tofacitinib, the rationale for vesicular systems in RA treatment, and the recent advances in vesicle-based Tofacitinib delivery. Preclinical data supporting the efficacy and safety of such systems are critically analyzed, alongside a discussion on formulation strategies, characterization techniques, and translational challenges. The integration of nanotechnology with JAK inhibition offers a forward-looking approach for the effective management of RA, with potential to reshape the therapeutic landscape.

References

  1. Pannu, Shivani, Rahul Pal, and Inderjeet Verma. “Exploring the Therapeutic Potential of Nanocarrier-Mediated Drug Delivery in Rheumatoid Arthritis (RA) Treatment.” Current Rheumatology Reviews(2025).
  2. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2024;403(10317):1276-1288.
  3. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2023;402(10306):918–932.
  4. Singh JA, Saag KG, Bridges SL Jr, et al. 2023 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2023;75(4):472–492.
  5. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in RA. N Engl J Med. 2023;388(8):701–711.
  6. US FDA. Tofacitinib Drug Approval Summary. Accessed June 2025.
  7. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2022;314(1):9–19.
  8. van Vollenhoven RF, et al. Tofacitinib vs adalimumab in RA: ORAL Strategy trial. N Engl J Med. 2022;387:2493–2504.
  9. Cohen SB, Tanaka Y, Mariette X, et al. Safety profile of Tofacitinib: an updated integrated analysis. Rheumatology. 2024;63(3):456–467.
  10. S. Food and Drug Administration. FDA Drug Safety Communication: Safety trial finds increased risk of serious heart-related events with JAK inhibitors. 2021.
  11. Choudhury H, Pandey M, Yee C, et al. Hyaluronic Acid-Decorated Transfersomes for Enhanced Transdermal Delivery of Tofacitinib. Carbohydr Polym. 2023;301:120353.
  12. Sharma A, Kumar R, Sharma S. Chondroitin Sulfate-Coated Proglycosomes for Targeted Delivery of Tofacitinib. J Drug Deliv Sci Technol. 2022;68:103014.
  13. Zhang Y, Wang L, Chen C, et al. Transdermal Patch and Microneedle Systems for Tofacitinib: Comparative Evaluation in Arthritic Rats. Pharmaceutics. 2025;17(2):311.
  14. Alkilani AZ, McCrudden MT, Donnelly RF. Microneedle-Mediated Transdermal Delivery of Tofacitinib: Preclinical Assessment. Eur J Pharm Biopharm. 2023;189:147–155.
  15. O’Shea JJ, Gadina M, Siegel RM. Cytokines and JAK-STAT Signaling in Immunity and Disease. N Engl J Med. 2023;389(17):1604–1615.
  16. Dowty ME, Lin J, Ryder TF, et al. The Pharmacokinetics, Metabolism, and Clearance of Tofacitinib in Humans. Drug Metab Dispos. 2020;48(4):348–357.
  17. Pfizer Inc. XELJANZ® (Tofacitinib): U.S. Prescribing Information. Revised April 2024.
  18. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of Tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2019;367:495–507.
  19. S. FDA. Drug Approval History for Tofacitinib. Updated June 2025.
  20. van Vollenhoven RF, et al. Tofacitinib or Adalimumab vs Placebo in RA Patients: The ORAL Standard Trial. Lancet. 2021;398(10317):1264–1276.
  21. Smolen JS, Landewé RBM, et al. Long-Term Safety and Effectiveness of JAK Inhibitors in RA: Real-World Data. Ann Rheum Dis. 2024;83(2):145–153.
  22. Cohen S, et al. Updated Safety Analysis of Tofacitinib in Rheumatoid Arthritis: A Post-Marketing Perspective. Arthritis Res Ther. 2023;25(1):19.
  23. S. FDA. FDA Drug Safety Communication: Increased Risk with JAK Inhibitors. 2021.
  24. Choudhury H, Pandey M, Yee C, et al. Hyaluronic Acid-Coated Transfersomes for Enhanced Delivery of Tofacitinib. Carbohydr Polym. 2023;301:120353.
  25. Cohen S, Tanaka Y, Mariette X, et al. Long-term safety profile of Tofacitinib in RA: an updated integrated analysis. Rheumatology. 2024;63(3):456–467.
  26. Singh JA, Saag KG, et al. 2023 American College of Rheumatology Guidelines for RA. Arthritis Rheumatol. 2023;75(4):472–492.
  27. Mehta M, De Jesus Andreoli Pinto T, et al. Lipid-based nanocarriers in drug delivery: clinical perspectives. Pharmaceutics. 2024;16(3):379.
  28. Barenholz Y. Doxil® — the first FDA-approved nano-drug: lessons learned. J Control Release. 2023;345:89–101.
  29. Pandey M, Choudhury H, et al. Hyaluronic acid-decorated nanocarriers for targeted drug delivery. Carbohydr Polym. 2023;301:120353.
  30. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2022;314(1):9–19.

How to cite

–

Journal

Journal of Integrated Research (Agriculture & Life Sciences)

ISSN

3093-4931

Periodicity

Annual

Leading Research Intensive & Industry Driven University
Study at Leading Research Intensive
& Industry Driven University

University Campus

Desh Bhagat University,
Off to NH-44, Amloh Road, Mandi Gobindgarh,
District Fatehgarh Sahib, Punjab- 147301, India